News

← News

Published on April 07, 2016

CONTACT INFORMATION

Peter Ciano (732) 823-4950

pciano@trispharma.com

Tris Pharma Announces Appointment of Chief Commercial Officer of its New Brand Business

MONMOUTH JUNCTION, NJ, April 7, 2016 / PRNewswire/ - Tris Pharma, Inc. ("Tris") a specialty pharmaceutical company with a robust portfolio of approved NDA’s and late-stage pipeline of innovative technology based product candidates for the treatment of Attention-Deficit Hyperactivity Disorder ("ADHD"), today announced that it has appointed Sharon Clarke to the position of Chief Commercial Officer to lead Tris’ brand business and launch its first commercial product .

With nearly 30 years of experience in the specialty pharma and life sciences industry, Ms. Clarke has held senior management positions in top-tier biopharmaceutical companies. Sharon was most recently Head of Commercial Operations of Virginia based Kaleo Inc. Sharon started her career as a Medical Sales Representative in 1986 at Wallace Laboratories and quickly grew through ranks and successor companies to become President, General Manager and Board Member of the US business of Meda Pharmaceuticals, the US arm of a Swedish multinational. Sharon became President and General Manager in 2008 and under her tenure Meda's US annual sales exceeded $300 million.

"Sharon has an outstanding record of success in biopharmaceutical sales and marketing" said Ketan Mehta, President and Chief Executive Officer of Tris. "For the last several months Sharon has been a consultant to Tris, shaping the commercial organization. During that time I've seen how impactful she can be. Her leadership and broad commercial experience strengthens our management team at a key juncture as we get ready to launch our first branded product."

"It is hard not to be excited about joining a company dedicated to improving healthcare in children," said Ms. Clarke. "While Tris has leveraged its technology platform to generate seven approved NDA's, the company has historically partnered its products. With our first NDA commercial launch upon us, I look forward leading our commercial organization and bringing Tris' potentially life changing therapies to patients with a significant unmet need."

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse; technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D, manufacturing and commercial facilities are located in Monmouth Junction, New Jersey, U.S.A.

For more information, please visit www.trispharma.com